Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Autologous Adipose-Derived Regenerative Cells (ADRCs) Injection for Improving Diminished Ovarian Reserve (ARISE) - A Single-arm Self-controlled Study

NCT07117682 is registered in ClinicalTrials.gov with Cytori Therapeutics as lead sponsor.

NCT NCT07117682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07117682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Autologous Adipose-Derived Regenerative Cells (ADRCs) Injection for Improving Diminished Ovarian Reserve (ARISE) - A Single-arm Self-controlled Study
Lead sponsor
Cytori Therapeutics
Phase
Not applicable
Overall status
Not yet recruiting
Start date
August 25, 2025
Completion date
August 1, 2027
Enrollment
25 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diminished ovarian reserve (dor), ovarian failure, premature, primary ovarian insufficiency (poi)